A quadruple therapy synergistically blocks proliferation and promotes apoptosis of hepatoma cells

Oncology Reports

Volumn 11, Issue 5, 2004, Pages 943-950

  Ganslmayer, Marion ^a   Ocker, Matthias ^a   Zopf, Steffen ^a   Leitner, Sandra ^a   Hahn, Eckhart G ^a   Schuppan, Detlef ^a   Herold, Christoph ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Biomodulator; Combinatory treatment; Hepatocellular carcinoma; Retinoids; Tamoxifen; Trichostatin A

Indexed keywords

ANTIESTROGEN; ANTINEOPLASTIC AGENT; BAX PROTEIN, HUMAN; BAX PROTEIN, MOUSE; BAX PROTEIN, RAT; BIOLOGICAL RESPONSE MODIFIER; CASP3 PROTEIN, HUMAN; CASP3 PROTEIN, MOUSE; CASP3 PROTEIN, RAT; CASPASE; CASPASE 3; CDKN1A PROTEIN, HUMAN; CDKN1A PROTEIN, MOUSE; CDKN1A PROTEIN, RAT; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; CYCLOHEXANE DERIVATIVE; DNA; ENZYME INHIBITOR; FUMAGILLOL CHLOROACETYLCARBAMATE; HYDROXAMIC ACID; O-(CHLOROACETYLCARBAMOYL)FUMAGILLOL; PROTEIN BAX; PROTEIN BCL 2; RETINOIC ACID; SESQUITERPENE; TAMOXIFEN; TRICHOSTATIN A;

ANIMAL; APOPTOSIS; ARTICLE; BIOSYNTHESIS; CELL CYCLE; CELL DIVISION; DRUG EFFECT; DRUG POTENTIATION; ENZYME ACTIVATION; HUMAN; LIVER CELL CARCINOMA; METABOLISM; MOUSE; PATHOLOGY; RAT; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BIOLOGICAL RESPONSE MODIFIERS; CARCINOMA, HEPATOCELLULAR; CASPASE 3; CASPASES; CELL CYCLE; CELL DIVISION; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; CYCLOHEXANES; DNA; DRUG SYNERGISM; ENZYME ACTIVATION; ENZYME INHIBITORS; ESTROGEN ANTAGONISTS; HUMANS; HYDROXAMIC ACIDS; MICE; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS; SESQUITERPENES; TAMOXIFEN; TRETINOIN;

EID: 16544389873     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.11.5.943     Document Type: Article

References (31)

1. Bosch FX, Ribes J and Boras J: Epidemiology of primary liver cancer. Sem Liver Dis 19: 271-285, 1999. (Pubitemid 29488770)
2. Herold C, Reck T, Fischler P, et al: Prognosis of a large cohort of patients with hepatocellular carcinoma in a single European center. Liver 22: 23-28, 2002. (Pubitemid 34552521)
3. Treiber G: Systemic treatment of hepatocellular carcinoma. Dig Dis 19: 311-323, 2001.
4. Herold C, Ganslmayer M, Ocker M, et al: Combined in vitro anti-tumoral action of Tamoxifen and retinoic acid derivatives in hepatoma cells. Int J Oncol 20: 89-96, 2002.
5. El Etreby MF, Ling and Lewis RW: Induction of apoptosis by mifepristone and tamoxifen in human LNCaP prostate cancer cells in culture. Prostate 43: 31-42, 2000. (Pubitemid 30164241)
6. CLIP Group: Tamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trial. Lancet 352: 17-20, 1998.
7. Muto Y, Moriwaki H and Saito A: Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. N Engl J Med 340: 1046-1047, 1999. (Pubitemid 29157643)
8. Minucci S and Pelicci PG: Retinoid receptors in health and disease: co-regulators and the chromatin connection. Semin Cell Dev Biol 10: 215-225, 1999. (Pubitemid 129502413)
9. Gianni M, Ponzanelli I, Mologni L, et al: Retinoid-dependent growth inhibition, differentiation and apoptosis in acute promyelocytic leukemia cells. Expression and activation of caspases. Cell Death Differ 7: 447-460, 2000. (Pubitemid 30255713)
10. Kin M, Torimura T, Ueno T, et al: Angiogenesis inhibitor TNP-470 suppresses the progression of experimentally-induced hepatocellular carcinoma in rats. Int I Oncol 16: 375-382, 2000.
11. Takatsuka S, Yamada N, Sawada T, et al: Contribution of angiogenesis to the progression of colon cancer: possible inhibitory effect of angiogenesis inhibitor TNP-470 on tumor growth and hepatic metastasis. Int J Oncol 17: 253-258, 2000.
12. Farinelle S, Malonne H, Chaboteaux C, et al: Characterization of TNP-470-induced modifications to cell functions in HUVEC and cancer cells. J Pharmacol Toxicol Methods 43: 15-24, 2000.
13. Zhang YI, Griffith EC, Sage J, et al: Cell cycle inhibition by the anti-angiogeneic agent TNP470 is mediated by p53 and p21. Proc Natl Acad Sci USA 97: 6427-6432, 2000. (Pubitemid 30412730)
14. Herold C, Ganslmayer M, Ocker M, et al: Trichostatin A blocks proliferation and triggers apoptosis in heptoma cells. J Hepatol 36: 233-240, 2002.
15. Medina V, Edmonds B, Young GP, et al: Induction of caspase-3 protease activity and apoptosis by butyrate and trichostatin A (inhibitors of histone deacetylase): dependence on protein synthesis and synergy with a mitochondrial/cytochrome c-dependent pathway. Cancer Res 57: 3697-3707, 1997. (Pubitemid 27381212)
16. Vigushin DM and Coombes RC: Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs 3: 1-13, 2002. (Pubitemid 34169522)
17. Jung M: Inhibitors of histone deacetylase as new anticancer agent. Curr Med Chem 8: 1505-1511, 2001.
18. Mandlekar S, Hebbar V, Christov K and Kong AN: Pharmacodynamics of tamoxifen and its 4-hydroxy and N-desmethyl metabolites: activation of caspases and induction of apoptosis in rat mammary tumors and in human breast cancer cell lines. Cancer Res 60: 6601-6606, 2000.
19. Mandlekar S and Kong AN: Mechanisms of tamoxifen-induced apoptosis. Apoptosis 6: 469-477, 2001. (Pubitemid 33078758)
20. Hansen LA, Sigman CC, Andreola F, et al: Retinoids in chemoprevention and differentiation therapy. Carcinogenesis 21: 1271-1279, 2000. (Pubitemid 30455984)
21. Fontana JA: Interaction of retinoids and tamoxifen on the inhibition of human mammaty cell proliferation. Exp Cell Biol 55: 136-144, 1986.
22. Ogawa H, Sato Y, Kondo M, et al: Combined treatment with TNP-470 and 5-fluorouracil effectively inhibits growth of murine colon cancer cells in vitro and liver metastasis in vivo. Oncol Rep 7: 467-72, 2000.
23. Logothetis CJ, Wu KK, Finn LD, Daliani D, et al: Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer. Clin Cancer Res 7: 1198-1203 2001. (Pubitemid 32708670)
24. Marks PA, Richon VM, Breslow R and Rifkind RA: Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol 13: 477-483, 2001. (Pubitemid 33027900)
25. Martinez LA, Yang J, Vazquez ES, et al: p21 modulates threshold of apoptosis induced by DNA-damage and growth factor withdrawal in prostate cancer cells. Carcinogenesis 23: 1289-1296, 2002.
26. Wu Q, Kirschmeier P, Hockenberry T, et al: Transcriptional regulation during p21/WAF1/Cip1-induced apoptosis in human ovarian cancer cells. J Biol Chem 277: 36329-36337, 2002.
27. Wieder T, Essmann F, Prokop A, et al: Activation of caspase-8 in drug-induced apoptosis of B-lymphoid cells is independent of CD95/Fas receptor-ligand interaction and occurs downstream of caspase-3. Blood 97: 1378-1387, 2001. (Pubitemid 32183762)
28. Schneider SM, Offterdinger M, Huber H and Grunt TW: Involvement of nuclear steroid/thyroid/retinoid receptors and of protein kinases in the regulation of growth and ofc-erbB and retinoic acid receptor expression in MCF-7 breast cancer cells. Breast Cancer Res Treat 58: 171-181, 1999. (Pubitemid 30032490)
29. McKenna NJ and O'Malley BW: Nuclear receptors, coregulators, ligands, and selective receptor modulators: making sense of the patchwork quilt. Ann NY Acad Sci 949: 3-5, 2001.
30. Ferrara FF, Fazi F, Bianchini A, et al: Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Res 61: 2-7, 2001. (Pubitemid 32095688)
31. Nagy L, Kao HY, Chakravarti D, et al: Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. Cell-89: 373-380, 1997. (Pubitemid 27220882)